We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.92 | -0.63% | 145.90 | 147.175 | 145.95 | 146.70 | 6,182,981 | 00:52:45 |
From Apr 2019 to Apr 2024
By George Stahl
Johnson & Johnson (JNJ) received a favorable verdict Thursday from a Texas jury in a trial regarding the company's all-metal hip-implant product.
The company was found not liable in a suit concerning Ultamet's metal-on-metal hip-replacement product, made by J&J's DePuy unit. Sales of the product were discontinued in May 2013 because of low demand and alternative hip products.
In a statement, a DePuy spokeswoman said the company was pleased with the jury's decision.
The jury verdict represented the first one in this round of litigation.
As of June 29, about 6,600 lawsuits involving Ultamet had been filed in state and federal court, most of which have been coordinated in the U.S. District Court for the Northern District of Texas.
J&J, which expects additional cases to be tried in the coming months, has said it is committed to fighting the allegations.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
